Adverse events after pleurodesis in patients with malignant pleural effusion

Imagem de Miniatura
Arquivos
art_TERRA_Adverse_events_after_pleurodesis_in_patients_with_malignant_2020.PDF.pdf (404.38 KB)
Citações na Scopus
3
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
AME PUBL CO
Autores
Citação
JOURNAL OF THORACIC DISEASE, v.12, n.7, p.3507-3513, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Malignant pleural effusion (MPE) is an important sign of advanced disease in metastatic cancer. Pleurodesis is one option to treat recurrent MPE. The Inflammatory response after pleurodesis may lead to important adverse events (AE) in a set of very ill patients. Methods: Retrospective analysis of patients submitted to pleurodesis (2009-2013). Clinical and laboratory data were collected. We compare the values in the day of pleurodesis, 2nd, 5th and 10th days after. Results: One hundred fourteen patients were undergone to pleurodesis with silver nitrate (46%), iodine (52%) and talc (2%). Female was the most frequent (86%) and the breast cancer was the most common primary site. The most frequent adverse event was low hemoglobin account (37), followed by pain (31). 68% of patients presented AEs and 28% had at least one AE with grade 3 or higher. The most altered was CRP that peaked in the 5th day after pleurodesis. Changes in CRP curve were less severe with the use of iodine when compared with the other two agents. Conclusions: Pleurodesis leads to important systemic inflammatory response detected by different serum markers. The occurrence of adverse events in this set of patients was great number of events with being marked as grade 3 or higher.
Palavras-chave
Pleural effusion, pleurodesis, adverse effects
URI
https://observatorio.fm.usp.br/handle/OPI/37691
Referências
  1. Neto JDA, 2015, RESPIRATION, V90, P369, DOI 10.1159/000440727
  2. Boshuizen RC, 2017, LUNG CANCER, V108, P9, DOI 10.1016/j.lungcan.2017.01.019
  3. Campos JRM, 1997, LANCET, V349, P251, DOI 10.1016/S0140-6736(05)64860-X
  4. de Campos JRM, 2001, CHEST, V119, P801, DOI 10.1378/chest.119.3.801
  5. Eisinger F, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00317
  6. Janssen JP, 2007, LANCET, V369, P1535, DOI 10.1016/S0140-6736(07)60708-9
  7. KENNEDY L, 1994, CHEST, V106, P342, DOI 10.1378/chest.106.2.342
  8. Kuzniar TJ, 2006, ANN THORAC SURG, V82, P1976, DOI 10.1016/j.athoracsur.2006.06.040
  9. Maskell NA, 2004, AM J RESP CRIT CARE, V170, P377, DOI 10.1164/rccm.200311-1579OC
  10. NCI (National Cancer Institute), 2009, COMM TERM CRIT ADV E
  11. Rehse DH, 1999, AM J SURG, V177, P437, DOI 10.1016/S0002-9610(99)00075-6
  12. Roberts ME, 2010, THORAX, V65, P32, DOI 10.1136/thx.2010.136994
  13. Rodriguez-Panadero F, 2012, RESPIRATION, V83, P91, DOI 10.1159/000335419
  14. Shaw P, 2004, COCHRANE DB SYST REV, V1, DOI [10.1002/14651858.CD002916.pub2, DOI 10.1002/14651858.CD002916.PUB2]
  15. Taghizadeh N, 2017, CHEST, V151, P845, DOI 10.1016/j.chest.2016.11.010
  16. Terra RM, 2015, RESPIRATION, V89, P276, DOI 10.1159/000371470
  17. Thomas R, 2017, JAMA-J AM MED ASSOC, V318, P1903, DOI 10.1001/jama.2017.17426
  18. Werebe EC, 1999, CHEST, V115, P190, DOI 10.1378/chest.115.1.190
  19. Xia H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087060

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/09
Artigos e Materiais de Revistas Científicas - LIM/61
Artigos e Materiais de Revistas Científicas - ODS/03